Navigation Links
American Brain Tumor Association’s 2013 Patient & Family Conference Highlights Emerging Research
Date:6/25/2013

Chicago, IL (PRWEB) June 25, 2013

The American Brain Tumor Association’s 2013 Patient & Family Conference, taking place in Chicago on Fri., July 26 and Sat., July 27, focuses on the medical, rehabilitative, social and wellness needs of brain tumor patients and their caregivers as well as brain tumor research updates.

“There is a growing movement in science toward patient-centric research – placing the patient, who is living with the disease, at the center of the investigative setting. Patients and caregivers are assuming greater roles in the formation of both initial research questions and clinical trial designs,” said Elizabeth Wilson, ABTA president and CEO. “This meeting is one example of the ways in which the ABTA brings researchers and patients together to discuss the impact of the disease and approaches to changing brain tumor research outcomes.”

As the first national non-profit organization to fund brain tumor research, the ABTA has been credited with seeding the modern day research field through its funding of successive generations of researchers since the 1970s. The organization’s research grants are awarded with a unique condition of support: study findings are reported to patients and caregivers directly impacted by the disease. This is often the first opportunity for scientists to have a conversation with someone living with the disease, and for patients to better understand research and research outcomes challenges.

Day one of the meeting program includes an overview of the advances in brain tumor research and areas of emerging interest, and a poster session during which researchers share their study findings with attendees. The second day of the meeting integrates holistic approaches to wellness and strategies for patients and caregivers adjusting to and living with the diagnosis, its treatments, and brain tumor survivorship.

The 2013 American Brain Tumor Association Patient & Family Conference is being held at the Renaissance Chicago O’Hare Suites Hotel, 8500 W. Bryn Mawr Ave. in Chicago. To register, visit http://www.braintumorconference.org or call 800-886-ABTA (2282).

Sponsors for the 2013 Patient & Family Conference include Genentech, Inc., Northwest Biotherapeutics, The University of Chicago Medical Center, Alexian Brothers Neuroscience Institute, Cleveland Clinic Brain Tumor and Neuro-Oncology Center, NorthShore University HealthSystem, Novocure Inc., Procure Proton Therapy Center, The Northwestern Brain Tumor Institute and The Ohio State University.

ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION
Founded in 1973, the American Brain Tumor Association was first and is now the only national organization committed to funding brain tumor research and providing support and education programs for all tumor types and all age groups. For more information, visit http://www.abta.org.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10856697.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Clinical news alert from the American Academy of Orthopaedic Surgeons
2. American College of Cardiology cites new USF Simulation Center for Training Excellence
3. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
4. Young Americans Need to Cut Calorie Intake: Study
5. Hutchinson Center president elected to American Academy of Art and Sciences
6. Can weight loss help African-American breast cancer survivors?
7. Americans Support Medicare Reform, But Not on Their Dime: Poll
8. One-third of adult Americans with arthritis battle anxiety or depression
9. Equal access to care helps close survival gap for young African-American cancer patients
10. Systemic sclerosis complications more severe in African Americans than Caucasians
11. 53 million Americans might have diabetes by 2025, according to a new study in Population Health Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... ... A man who has struggled to quit smoking, a man who has struggled with hair ... solutions to his problems – and he did. Now Nabat, a serial entrepreneur featured as ... breakthrough inventions to the world and better people's lives. His own experience with nicotine addiction ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running and ... companies. Attendees also get to see the most incredible gardens and home improvement ... , at the Colorado Convention Center - 700 14th St. Denver CO, is an ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Company, Inc. (NYSE MKT: AXN) today announced that for the ... the Company achieved revenue of $8,195,839, a 27% improvement on ... 2015. --> --> The ... $2,068,635, or $.03 per share, up 265% from the net ... of fiscal year 2015. Gross margin for the three months ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology: